Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Don’t Use Topiramate In Pregnancy Unless No Other Drug Is Available, Says EU Drug Safety Committee

Executive Summary

The European Medicines Agency’s pharmacovigilance committee said its safety review of topiramate took account of available data including three recent observational studies.

You may also be interested in...



EMA Probe Into Paternal Valproate Exposure Risk Continues After ‘Errors’ Found In Study

Initial results from a study indicate that children born to men taking valproate medicines are at an increased risk of having neurodevelopmental disorders, but “important limitations” and “errors” with the data highlight the need for further analysis.

Use of Gynecological Drugs Restricted In EU; ‘Urgent’ Safety Review Starts For Pholcodine

The European Medicines Agency has completed its investigation into the safety of nomegestrol and chlormadinone, and has started reviewing risks linked to the cough suppressant, pholcodine, and the epilepsy and migraine drug, topiramate.

EU Could Soon Have Three XBB.1.5 COVID-19 Vaccines For Winter Season

The head of the European Medicines Agency says a group of international regulators got together to ensure “global alignment” on the approach to be taken on COVID-19 vaccination. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148806

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel